AZD6765 for Treatment Resistant Depression
Study identifier:D6702C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase IIa, Multi-Center, Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess the Antidepressant Effect and Onset of Effect of AZD6765 in Treatment-Resistant Major Depressive Disorder Patients
Medical condition
Depression
Phase
Phase 2
Healthy volunteers
No
Study drug
AZD6765
Sex
All
Actual Enrollment
34
Study type
Interventional
Age
21 Years - 65 Years
Date
Study Start Date: 01 Jul 2007
Primary Completion Date: 01 Nov 2007
Study Completion Date: 01 Nov 2007
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Jan 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Mark Smith
AstraZeneca
